TP53 and ovarian cancer: ,37 Historically, adavosertib was evaluated in both preclinical and clinical studies, including its combination with chemotherapy, such as a phase 2 study of adavosertib combined with carboplatin for the treatment of ovarian cancer with TP53 mutations17,38 and a phase 1 study combined with docetaxel and cisplatin for the treatment of pancreatic cancer.39